Sekiya Y, Sugita R, Terada K, Sawa Y, Nomura S
Sekiya Hirabari Mental Clinic.
Seishin Shinkeigaku Zasshi. 1995;97(8):605-22.
The effect of alpha 2-adrenoceptor agonist, clonidine (CLN) (100 micrograms/kg, i.p.), on the noradrenalin metabolite 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG)-total in the rat nucleus accumbens after desipramine (DMI) (20 mg/kg, i.p.) and clomipramine (CMI) (20 mg/kg, i.p.) treatment was estimated in the freely moving rat by intracerebral dialysis. Locomotor activity was measured simultaneously by the Animex. Locomotor activity in the control decreased after CLN administration, in accordance with the decrease in MHPG. The difference of locomotor activity and MHPG between the single dose trial with DMI, CMI and the control did not reach statistical significance throughout the experiment. The results suggest that a single injection of DMI and CMI have not an inhibitory effect on presynaptic alpha 2-adrenergic receptor in the nucleus accumbens. Next, DMI (20 mg/kg, i.p.) and CMI (20 mg/kg, i.p.) were injected once daily for 14 days and experiments, the same method as used on the single dose trial. A difference in locomotor activity and MHPG between the chronic DMI treatment and the control reached statistical significance. A significant reduction of locomotor activity was found during the 60 min period of the experiment. In addition, a significant reduction of MHPG was found during the 30-90 min period. A difference in locomotor activity and MHPG between the chronic CMI treatment and the control reached statistical significance. A significant reduction of locomotor activity was found during the 60 min period of the experiment. In addition, a significant reduction of MHPG was found during the 30-120 min period. The results suggest that the chronic DMI treatment and the chronic CMI treatment may diminish the CLN-induced reduction of MHPG via the subsensitivity of presynaptic alpha 2-adrenergic receptor in the nucleus accumbens.
通过脑内透析,在自由活动的大鼠中评估了α2-肾上腺素能受体激动剂可乐定(CLN)(100微克/千克,腹腔注射)对去甲丙咪嗪(DMI)(20毫克/千克,腹腔注射)和氯米帕明(CMI)(20毫克/千克,腹腔注射)处理后大鼠伏隔核中去甲肾上腺素代谢物3-甲氧基-4-羟基苯乙二醇(MHPG)总量的影响。同时用Animex测量运动活性。与MHPG的降低一致,CLN给药后对照组的运动活性降低。在整个实验中,DMI、CMI单剂量试验与对照组之间的运动活性和MHPG差异未达到统计学意义。结果表明,单次注射DMI和CMI对伏隔核突触前α2-肾上腺素能受体没有抑制作用。接下来,每天一次腹腔注射DMI(20毫克/千克)和CMI(20毫克/千克),持续14天进行实验,方法与单剂量试验相同。慢性DMI处理与对照组之间的运动活性和MHPG差异达到统计学意义。在实验的60分钟期间发现运动活性显著降低。此外,在30 - 90分钟期间发现MHPG显著降低。慢性CMI处理与对照组之间的运动活性和MHPG差异达到统计学意义。在实验的60分钟期间发现运动活性显著降低。此外,在30 - 120分钟期间发现MHPG显著降低。结果表明,慢性DMI处理和慢性CMI处理可能通过伏隔核突触前α2-肾上腺素能受体的敏感性降低来减轻CLN诱导的MHPG降低。